2-[(Benzyloxy)methyl]pyrrolidine | 148562-33-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(Benzyloxy)methyl]pyrrolidine
• 英文别名: 2-(phenylmethoxymethyl)pyrrolidine
• CAS: 148562-33-8
• 化学式: C₁₂H₁₇NO
• mdl: MFCD06653381
• 分子量: 191.273
• InChiKey: WZWVGKAJVSLHAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苄基缩水甘油醚 在 copper(l) iodide 、 sodium azide 、 bis(cyclohexanyl)borane 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二甲基亚砜 为溶剂， 反应 3.0h， 生成 2-[(Benzyloxy)methyl]pyrrolidine
  参考文献：
  名称：

  Jego, J. M.; Carboni, B.; Vaultier, M., Bulletin de la Societe Chimique de France, 1992, # 6, p. 554 - 565

  摘要：

  DOI：

文献信息

• Dipeptidyl peptidase-IV inhibitors
  申请人：Hulin Bernard

  公开号：US20050234065A1

  公开（公告）日：2005-10-20

  The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R 1 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.

  该发明提供了Formula (I)的化合物或其前药，或者该化合物或前药的药用可接受盐，或者该化合物、前药或盐的溶剂化合物，其中A、N、X和R1如本文所定义；以及这些药物组合物；以及使用这些药物组合物治疗疾病的方法，包括2型糖尿病、1型糖尿病、糖耐量受损、高血糖、代谢综合征（综合征X和/或胰岛素抵抗综合征）、葡萄糖尿病、代谢性酸中毒、关节炎、白内障、糖尿病神经病、糖尿病肾病、糖尿病视网膜病、糖尿病心肌病、肥胖、由肥胖恶化的疾病、高血压、高脂血症、动脉粥样硬化、骨质疏松症、脆弱、骨质流失、骨折、急性冠状动脉综合征、生长激素缺乏引起的矮小症、多囊卵巢综合征引起的不孕症、焦虑、抑郁、失眠、慢性疲劳、癫痫、进食障碍、慢性疼痛、酒精成瘾、与肠道蠕动相关的疾病、溃疡、肠易激综合征、炎症性肠病；短肠综合征；以及预防2型糖尿病疾病进展。
• Dpp-IV Inhibitors
  申请人：Edwards Paul John

  公开号：US20080176838A1

  公开（公告）日：2008-07-24

  The invention relates to compounds of formula (I) wherein R 1-9 , Z, n, X, A, and R b have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament for the treatment of type 2 diabetes mellitus, obesity and lipid disorders.

  该发明涉及式(I)的化合物，其中R1-9、Z、n、X、A和Rb的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及将其作为药物用于治疗2型糖尿病、肥胖和脂质紊乱的生产和使用。
• [EN] PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TRIAZINE DISUBSTITUÉS PHARMACEUTIQUEMENT ACTIFS
  申请人：LEAD DISCOVERY CENTER GMBH

  公开号：WO2012117048A1

  公开（公告）日：2012-09-07

  The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.

  本发明涉及二取代三嗪衍生物和/或其药用可接受盐，这些衍生物作为药用活性剂的使用，特别用于预防和/或治疗传染病，包括机会性疾病、免疫疾病、自身免疫疾病、心血管疾病、细胞增殖性疾病、炎症、勃起功能障碍和中风，以及含有至少一种所述二取代三嗪衍生物和/或其药用可接受盐的药物组合物。此外，本发明涉及所述二取代三嗪衍生物作为蛋白激酶抑制剂的使用。
• Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor
  申请人：Scheinberg David

  公开号：US20050272667A1

  公开（公告）日：2005-12-08

  The present invention provides analog and derivative compounds of (S,S,R)-(−)-actinonin and methods of asymmetric synthesis thereof having a structure: where R 1 is hydrogen, C(O)R 6 or R 1 in combination with N is 2-oxomorpholine, R 2 is hydrogen, methyl, CH 2 CH(CH 3 ) 2 , (CH 2 ) 2 CH 3 , CH(CH 3 ) 2 , (CH 2 ) 3 CH 3 , (CH 2 ) 4 NH 2 , (CH 2 ) 3 CO 2 H, phenyl, 3,4-dichlorophenyl, biphenyl, benzyl, 4-hydroxybenzyl, piperidine, N-Boc-4-piperidine, CH 2 -(N-Boc-4-piperidine), 4-tetrahydropyran, CH 2 -4-tetrahydropyran, 3-methyl indolyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, 3-thienyl, R 3 is R 2 or C 3-8 alkyl, R 4 is C 1-3 alkyl, R 5 is NH 2 , OH, NHOH, NHOCH 3 , N(CH 3 )OH, N(CH 3 )OCH 3 , NHCH 2 CH 3 , NH(CH 2 CH 3 ), NHCH 2 (2,4-(OCH 3 ) 2 Ph, NHCH 2 (4-NO 2 )Ph, NHN(CH 3 ) 2 , proline, or 2-hydroxymethyl pyrrolidine and R 6 is an optionally substituted or halogenated alkyl, aryl, heteroalkyl or heteroaryl amine where R 6 further comprising a cyclic or bicyclic structure. Also provided are methods for treating a neoplastic disease or for inhibiting tumor cell growth using the compounds present invention or using the compound (S,S,R)-(−)-actinonin.

  本发明提供了(S,S,R)-(−)-阿克替诺宁的类似物和衍生物化合物，以及不对称合成方法，其具有以下结构：其中R1是氢、C(O)R6或R1与N的组合是2-氧代吗啉，R2是氢、甲基、 CH(CH3)2、(CH2)2 、CH( )2、( )3 、( )4NH2、( )3CO2H、苯基、3,4-二氯苯基、联苯、苄基、4-羟基苄基、哌啶基、N-叔丁氧羰基-4-哌啶基、 -(N-叔丁氧羰基-4-哌啶基)、4-四氢吡喃基、 -4-四氢吡喃基、3-甲基吲哚基、2-萘基、3-吡啶基、4-吡啶基、3-噻吩基，R3是R2或C3-8烷基，R4是C1-3烷基，R5是NH2、OH、NHOH、NHO 、N( )OH、N( )O 、NH 、NH( )、NH (2,4-二甲氧基苯基)、NH (4-硝基苯基)、NHN( )2、脯氨酸或2-羟甲基吡咯烷，R6是可选择取代或卤代的烷基、芳基、杂环烷基或杂环芳基胺，其中R6还包括一个环状或双环结构。此外，还提供了使用本发明的化合物或使用化合物(S,S,R)-(−)-阿克替诺宁来治疗肿瘤性疾病或抑制肿瘤细胞生长的方法。
• Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor
  申请人：——

  公开号：US20020198156A1

  公开（公告）日：2002-12-26

  The present invention provides methods for the asymmetric synthesis of (S,S,R)-(−)-actinonin and its analogs and the compounds thereby synthesized having a structural formula: 1 where R 1 is an optionally substituted or halogenated alkyl, aryl, heteroalkyl or heteroaryl amine, said R 1 further comprising a cyclic or bicyclic structure; R 2 is methyl, CH 2 CH 3 , (CH 2 ) 2 CH 3 , C(CH 3 ) 3 , phenyl, 3,4-dichiorophenyl, biphenyl, benzyl, 4-hydroxybenzyl, piperidine, N-Boc-4-piperidine, CH 2 -(N-Boc-4-piperidine), 4-tetrahydropyran, CH 2 -4-tetrahydropyran, 3-methyl indolyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, 3-thienyl; R 3 is R 2 or C 3-8 alkyl, R 4 is C 1-3 alkyl; and R 5 is NH 2 , OH, NHOH, NHOCH 3 , N(CH 3 )OH, N(CH 3 )OCH 3 , NHCH 2 CH 3 , NH(CH 2 CH 3 ), NHCH 2 (2,4-(OCH3) 2 Ph, NHCH 2 (4-NO 2 )Ph, NHN(CH 3 ) 2 , proline, or 2-hydroxymethyl pyrrolidine. Additionally, a method for the treatment of a neoplastic disease or for the inhibition of tumor cell growth each comprising the step of administering to an individual in need of such treatment a pharmacologically effective dose of the compounds of the present invention are provided.

  本发明提供了(S,S,R)-(−)-actinonin及其类似物的不对称合成方法，所合成的化合物具有以下结构式：其中R1是可选择取代或卤代的烷基、芳基、杂环烷基或杂环芳基胺，R1还包括一个环状或双环结构；R2是甲基、 、(CH2)2 、C(CH3)3、苯基、3,4-二氯苯基、联苯、苄基、4-羟基苄基、哌啶基、N-Boc-4-哌啶基、 -(N-Boc-4-哌啶基)、4-四氢吡喃基、 -4-四氢吡喃基、3-甲基吲哚基、2-萘基、3-吡啶基、4-吡啶基、3-噻吩基；R3是R2或C3-8烷基，R4是C1-3烷基；R5是NH2、OH、NHOH、NHO 、N( )OH、N( )O 、NH 、NH( )、NH (2,4-(O )2Ph)、NH (4-NO2)Ph、NHN( )2、脯氨酸或2-羟甲基吡咯烷。此外，还提供了用于治疗肿瘤性疾病或抑制肿瘤细胞生长的方法，包括向需要此类治疗的个体给予本发明化合物的药理有效剂量。